Here are my notes from their concall
-
2 gaps in current portfolio: US frontend (valuations are not demanding, looking for an acquisition), India branded (valuations are crazy)
-
Everolimus should be a good product
-
Crop: Launching a pesticide for management of pink bollworm in cotton crop (pheromone based mating disruption technology)
-
Higher inventory because of:
o Agri inventory cycle requires inventory buildup in March quarter to service demand in June quarter
o COVID specific pharma portfolio requires high inventory buildup -
Domestic oncology portfolio has witnessed higher competition and pricing control from government along with covid specific demand glut (lower number of chemo therapies where Natco is dominant) – this is very high margin business
-
Targeting 7-8 filings/year over the next couple of years
-
Very bad flu season impacted US sales
-
Will not guide because market is very uncertain, Q1FY22 will be better than Q4FY21
-
Revlimid launch will be in March 2022, high single digit market share and exclusivity for certain time period along with 1/3rd profit share (1/3rd to Natco, rest to Teva)
Disclosure: Invested